The Denver Network of the NHLBI Progenitor Cell Biology Consortium

描述(由申请人提供)：本申请建议建立NHLBI前体细胞生物学联盟丹佛网络。这次RFA的时机恰好与丹佛的一项新的多机构干细胞倡议相吻合。2007年，科罗拉多丹佛大学(UCD)建立了一个新的再生医学和干细胞生物学项目(RMSCBP)，结果招聘了7名新教师，他们的研究重点是干细胞生物学。与这一倡议相一致，国家犹太人健康(NJH)招募了两名杰出的肺干细胞生物学家。这些新成员加入了24名现有教员的行列，组成了一个多机构的综合干细胞计划，由30多名初级成员组成，他们可以以折扣价(http://www.uchsc.edu/stemcell/).)使用最先进的核心设施本申请中提出的项目是去年由于这些新的干细胞倡议而启动的现有合作的极好例子。具体地说，这项申请建议利用丹佛网络在造血和皮肤干细胞生物学领域的现有专业知识来产生改进的试剂，以识别和表征肺和血管祖细胞谱系。此外，为了促进开发分离肺和血管干细胞和祖细胞的新方法，并指导这些细胞分化为所需的细胞命运，我们建议建立新的核心设施，利用丹佛网络成员开发的新技术。最后，将探索条件永生化长期造血干细胞和诱导多能干细胞(IPS)的治疗潜力，这些干细胞将通过新的非病毒方法产生，用于治疗血液和肺部疾病。科罗拉多州临床翻译科学研究所(CCTSI)将极大地促进这一应用程序的翻译和临床方面，以及拟议的指导和培训计划。UCD及其包括NJH在内的六个附属机构的临床和翻译科学、研究和培训最近在获得CTSA 7600万美元的奖励后成功纳入CCTSI。

DESCRIPTION (provided by applicant): This application proposes to establish the Denver Network of the NHLBI Progenitor Cell Biology Consortium. The timing of this RFA coincides perfectly with new a multi-institutional stem cell initiative in Denver. A new Regenerative Medicine and Stem Cell Biology Program (RMSCBP) was established at the University of Colorado Denver (UCD) in 2007, which has resulted in the recruitment of 7 new faculty whose research efforts focus on stem cell biology. In concert with this initiative, National Jewish Health (NJH) recruited two outstanding lung stem cell biologists. These new recruits have joined 24 existing faculty to form a multi-institutional, comprehensive stem cell program consisting of over 30 primary members who have access to state-of-the-art Core Facilities at discounted rates (http://www.uchsc.edu/stemcell/). The projects proposed in this application are excellent examples of existing collaborations that were initiated within the last year as a result of these new stem cell initiatives. Specifically, this application proposes to utilize the existing expertise within the Denver Network in the areas of hematopoietic and skin stem cell biology to generate improved reagents to identify and characterize lung and vascular progenitor cell lineages. In addition, to facilitate the development of new methods for isolating lung and vascular stem and progenitor cells, and for directing the differentiation of these cells to desired cell fates, we propose to establish new Core Facilities which utilize novel technologies developed by members of the Denver Network. Finally, the therapeutic potential of conditionally immortalized long-term hematopoietic stem cells and induced pluripotent stem (iPS) cells, which will be generated by novel non-viral methods, will be explored for the treatment of hematological and lung disorders. The translational and clinical aspects of this application, as well as the proposed mentoring and training program, will be greatly facilitated by the Colorado Clinical Translational Science Institute (CCTSI). The clinical and translation sciences, research, and training at UCD and its six Affiliates, which includes NJH, were recently successfully integrated into the CCTSI following the receipt of a CTSA award of $76 million.